A phase II study on Mefatinib as first-line treatment of patients with advanced non-small-cell lung cancer harboring uncommon EGFR mutations

doi:10.1002/cac2.12456

科研成果详情

名称	A phase II study on Mefatinib as first-line treatment of patients with advanced non-small-cell lung cancer harboring uncommon EGFR mutations
作者	Wang, Pingli 1; Cao, Liming 2; Tian, Panwen 3; Ren, Shengxiang 4; Miao, Liyun 5; Zhou, Chengzhi 6; Fan, Yun 7; Li, Yuping8; Lv, Dongqing 9; Zhao, Xin 10; Yang, Mei 11; Zhu, Chaonan 11; Yu, Bing 11; Xu, June 11; Song, Yong 12; Wang, Kai 1,13
发表期刊	CANCER COMMUNICATIONS
语种	英语
原始文献类型	Letter ; Early Access
其他关键词	AFATINIB
出版者	WILEY
ISSN	2523-3548
EISSN	2523-3548
卷号	43
期号	9
页码	1059-1063
DOI	10.1002/cac2.12456
页数	5
WOS类目	Oncology
WOS研究方向	Oncology
WOS记录号	WOS:001011185900001
收录类别	SCIE ; SCOPUS
发布日期	2023-06-15
URL	查看原文
PubMed ID	37322852
通讯作者地址	[Wang, Kai]Zhejiang Univ, Dept Resp & Crit Care Med, Affiliated Hosp 2, Sch Med, Hangzhou 310009, Zhejiang, Peoples R China. ; [Song, Yong]Gen Hosp Eastern Theater Command, Dept Resp Med, Nanjing 350025, Jiangsu, Peoples R China.
Scopus学科分类	Oncology;Cancer Research
SCOPUSEID	SCOPUS_ID:85161953991
引用统计
文献类型	其他
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/181660
专题	第一临床医学院（信息与工程学院）、附属第一医院_内科学_呼吸与危重症医学科
通讯作者	Song, Yong; Wang, Kai
作者单位	1.Zhejiang Univ, Dept Resp & Crit Care Med, Affiliated Hosp 2, Sch Med, Hangzhou 310009, Zhejiang, Peoples R China; 2.Cent South Univ, Xiangya Hosp, Dept Resp Med, Changsha, Hunan, Peoples R China; 3.Sichuan Univ, Dept Resp & Crit Care Med, West China Hosp, Chengdu, Sichuan, Peoples R China; 4.Shanghai Pulm Hosp, Dept Med Oncol, Shanghai, Peoples R China; 5.Nanjing Univ, Dept Resp Med, Drum Tower Hosp, Med Sch, Nanjing, Jiangsu, Peoples R China; 6.Guangzhou Med Univ, Dept Pulm & Crit Care Med, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China; 7.Univ Chinese Acad Sci, Dept Med Thorac Oncol, Canc Hosp, Hangzhou, Zhejiang, Peoples R China; 8.Wenzhou Med Univ, Dept Pulm & Crit Care Med, Affiliated Hosp 1, Wenzhou, Zhejiang, Peoples R China; 9.Taizhou Hosp Zhejiang Prov, Dept Resp Med, Taizhou, Zhejiang, Peoples R China; 10.Nanjing Med Univ, Jiangsu Prov Hosp, Dept Resp & Crit Care Med, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China; 11.Hangzhou ZhongMei HuaDong Pharmaceut Co, Huadong Global Dev Ctr, Hangzhou, Zhejiang, Peoples R China; 12.Gen Hosp Eastern Theater Command, Dept Resp Med, Nanjing 350025, Jiangsu, Peoples R China; 13.Zhejiang Univ, Dept Resp & Crit Care Med, Affiliated Hosp 4, Sch Med, Yiwu, Zhejiang, Peoples R China
推荐引用方式 GB/T 7714	Wang, Pingli,Cao, Liming,Tian, Panwen,et al. A phase II study on Mefatinib as first-line treatment of patients with advanced non-small-cell lung cancer harboring uncommon EGFR mutations. 2023.